Lenalidomide Ariti

Lenalidomide, the active ingredient in Lenalidomide Ariti, is an immunomodulatory drug presented as an oral formulation for oral use. It treats multiple myeloma and myelodysplastic syndromes with del(5q) chromosome abnormality in adult patients. GNH USA supplies Lenalidomide Ariti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is an immunomodulatory agent indicated for specific hematologic cancers. - Multiple myeloma (newly diagnosed): improves progression‑free survival when combined with dexamethasone. - Multiple myeloma (relapsed/refractory): extends overall survival in combination regimens. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and may improve peripheral blood counts.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels that may cause bruising. - Diarrhea: loose stools occurring during treatment. - Rash: skin eruptions of varying intensity. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound drop in neutrophils leading to serious infections. - Severe thrombocytopenia: markedly low platelets causing bleeding. - Secondary primary malignancies: emergence of new cancers. - Hepatic toxicity: liver enzyme elevations or injury. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should consider several safety measures. - Pregnancy contraindication: drug is category X and must not be used during pregnancy. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular CBC to detect neutropenia or thrombocytopenia. - Renal function: adjust dose in patients with impaired renal clearance. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. - Store at below 25°C: keep in the original pack, protect from moisture.

Lenalidomide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure and toxicity. - Concurrent use with anticoagulants (e.g., warfarin) without monitoring: heightened risk of bleeding. - Combination with other immunomodulatory agents: may amplify hematologic toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide efficacy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can affect renal function and increase bleeding risk. - Live vaccines: immunosuppression may reduce vaccine efficacy.